C
Candace Graff
Publications - 4
Citations - 189
Candace Graff is an academic researcher. The author has contributed to research in topics: Medicine & Tumor necrosis factor alpha. The author has an hindex of 2, co-authored 2 publications receiving 107 citations.
Papers
More filters
Journal ArticleDOI
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Julie M. Parmentier,Jeff Voss,Candace Graff,Annette Schwartz,Maria A. Argiriadi,Michael M. Friedman,Heidi S. Camp,Robert J. Padley,Jonathan S. George,Deborah Hyland,Matthew Rosebraugh,Neil Wishart,L. Olson,Andrew J. Long +13 more
TL;DR: The data presented here highlight the JAK1 selectivity of upadacitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.
Journal ArticleDOI
Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate.
Adrian D. Hobson,Michael J. McPherson,Martin E. Hayes,Christian Grosse,Xiang Li,Jian Zhou,Zhong Xu Wang,Yajie Yu,Jindong Yang,Liang Sun,Qiang Zhang,Pei Qu,Shi-wei Yang,Axel Hernandez,Shaughn Bryant,Suzanne Mathieu,Agnieszka Bischoff,Julia FitzGibbons,Ling Chen Santora,Lu Wang,Margaret M. Fettis,Xiaofeng Li,Christopher C. Marvin,Zhi Chao Wang,Meena V. Patel,Diana Schmidt,Tong Mei Li,John T. Randolph,Rodger F. Henry,Candace Graff,Yu Tian,Ana Laura Marquez Aguirre,Anurupa Shrestha +32 more
TL;DR: In this paper , a convergent synthetic route to enable multiple points of diversity, a series of glucocorticoid receptor modulators (GRM) were profiled for potency, selectivity and drug-like properties in vitro.
Journal Article
Venetoclax (ABT-199), a potent and selective BCL-2 inhibitor, is efficacious in NZB/WF1 mouse model of lupus nephritis and reduces human lymphocyte lifespan in vitro (BA4P.127)
Kristie M. Grebe,Stuart J. Perper,Liz O'Connor,Annette Schwartz,Christian Goess,Dawna Hartman,Susan V. Westmoreland,Candace Graff,Andrew J. Souers,Joel D. Leverson,Steven W. Elmore,L. Olson,Li Chun Wang +12 more
TL;DR: Venetoclax treatment dose-dependently reduced the incidence of severe proteinuria and prolonged survival compared to vehicle controls and attenuated glomerulonephritis, tubular dilatation, immune cell infiltrates and IgG deposition in the kidney.
Journal ArticleDOI
Correction to "Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate".
Adrian D. Hobson,Michael J. McPherson,Martin E. Hayes,Christian Grosse,X. Li,Jian Zhou,Zhong Xu Wang,Yajie Yu,Jindong Yang,Liang Sun,Qiang Zhang,Pei Qu,Shi-wei Yang,Axel Hernandez,Shaughn Bryant,Suzanne Mathieu,Agnieszka Bischoff,Julia FitzGibbons,Ling Chen Santora,Lu Wang,Margaret M. Fettis,Xiaofeng Li,Christopher C. Marvin,Zhi Chao Wang,Meena V. Patel,Diana Schmidt,Tong Mei Li,John T. Randolph,Rodger F. Henry,Candace Graff,Yu Tian,Ana Laura Marquez Aguirre,Anurupa Shrestha +32 more
TL;DR: The ABBV-3373, an anti-TNF Glucocorticoid Receptor Receptor Modulator Immunology Antibody Drug Conjugate, was discovered by as discussed by the authors .